Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients with High-risk Hepatocellular Carcinoma

Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-risk Hepatocellular Carcinoma»